The DOI matches its Crossref record; 60 of the 62 references it cites were found in a registry or an index.
Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study
Abstract
Background Curcumin, the principal curcuminoid derived from the spice turmeric, influences several biological mechanisms associated with major depression, namely those associated with monoaminergic activity, immune-inflammatory and oxidative and nitrosative stress pathways, hypothalamus-pituitary-adrenal (HPA) axis activity and neuroprogression. We hypothesised that curcumin would be effective for the treatment of depressive symptoms in individuals with major depressive disorder.Methods In a randomised, double-blind, placebo-controlled study, 56 individuals with major depressive disorder were treated with curcumin (500 mg twice daily) or placebo for 8 weeks. The primary measure was the Inventory of Depressive Symptomatology self-rated version (IDS-SR30). Secondary outcomes included IDS-SR30 factor scores and the Spielberger State-Trait Anxiety Inventory (STAI).Results From baseline to week 4, both curcumin and placebo were associated with improvements in IDS-SR30 total score and most secondary outcome measures. From weeks 4 to 8, curcumin was significantly more effective than placebo in improving several mood-related symptoms, demonstrated by a significant group x time interaction for IDS-SR30 total score (F1, 53=4.22, p=.045) and IDS-SR30 mood score (F1, 53=6.51, p=.014), and a non-significant trend for STAI trait score (F1, 48=2.86, p=.097). Greater efficacy from curcumin treatment was identified in a subgroup of individuals with atypical depression.Conclusions Partial support is provided for the antidepressant effects of curcumin in people with major depressive disorder, evidenced by benefits occurring 4 to 8 weeks after treatment.Limitations Investigations with larger sample sizes, over extended treatment periods, and with varying curcumin dosages are required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preliminary evidence indicates that add-on treatment with curcumin may promote antidepressant effects in patients with MDD [161, 162].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [161]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Tabachnick, B. G., & Fidell, L. S. (1983) · Cited by 79,882
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,766
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D. V., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,899
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
Spielberger, C. D. (2010) · The Corsini Encyclopedia of Psychology · doi:10.1002/9780470479216.corpsy0943 · Cited by 2,535
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Aggarwal, B. B., & Harikumar, K. B. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.06.010 · Cited by 2,139
Sharma, R. A., Gescher, A. J., & Steward, W. P. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.05.009 · Cited by 1,701
Research works printed but not linked: 1
- Milobedzka, 1910, Structure of curcumin, Ber. Dtsch. Chem. Ges., 43, 2163
Cited by
Sorted by citations
Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
Kunnumakkara, A. B., Bordoloi, D., Padmavathi, G., Monisha, J., Roy, N. K., Prasad, S., & Aggarwal, B. B. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13621 · Cited by 1,068
Amalraj, A., Pius, A., Gopi, S., & Gopi, S. (2016) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2016.05.005 · Cited by 976
Soleimani, V., Sahebkar, A., & Hosseinzadeh, H. (2018) · Phytotherapy Research · doi:10.1002/ptr.6054 · Cited by 556
Cellular and molecular mechanisms of curcumin in prevention and treatment of disease
Patel, S. S., Acharya, A., Ray, R. S., Agrawal, R. K., Raghuwanshi, R., & Jain, P. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1552244 · Cited by 529
The therapeutic potential of curcumin: A review of clinical trials
Salehi, B., Stojanović-Radić, Z. Z., Matejić, J. S., Sharifi‐Rad, M., Kumar, N. V. A., Martins, N. A., & Sharifi‐Rad, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.016 · Cited by 497
Metadata
- Authors
- Lopresti, A. L., Maes, M., Maker, G. L., Hood, S. D., & Drummond, P. D.
- Affiliations
- Murdoch University (AU)
- Deakin University (AU)
- The University of Western Australia (AU)
- Corresponding author
- Lopresti, Adrian L.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 167
- Pages
- 368-375
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2048063648
- Cited by
- 216
- References
- 62
- Citations by year
- 2026: 22 · 2025: 16 · 2024: 16 · 2023: 16 · 2022: 12 · 2021: 21 · 2020: 13 · 2019: 23 · 2018: 18 · 2017: 16 · 2016: 14 · 2015: 26 · 2014: 3
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Affective Disorders (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Murdoch University Research Portal (submittedVersion)
- Funders
- Arjuna Natural Extracts Limited
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- curcumin, major depressive disorder, antidepressant effects, atypical depression, depressive symptoms, anxiety, neuroinflammation, oxidative stress, hypothalamic-pituitary-adrenal axis, turmeric, natural product therapy
- MeSH terms
- Adult, Affect, Antidepressive Agents, Curcumin, Depressive Disorder, Major, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Psychometrics, Surveys and Questionnaires, Western Australia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
